Aloe Cadabra to hit H-E-B shelves
VENTURA, Calif. — Aloe Cadabra has gained retail distribution at H-E-B.
The brand, which is touted as the first all-natural personal lubricant made with 95% certified organic aloe vera, also is available at Albertsons and The Vitamin Shoppe, the company said.
Aloe Cadabra is an all-natural line completely free of parabens, glycerin and harmful petroleum products. The line consists of three varieties made with aloe and vitamin E oil, along with such aromatic essential oils as Tahitian vanilla and French lavender, the company added.
Aloe Cadabra will be featured on H-E-B shelves beginning mid-April.
Study: Vimovo ‘well-tolerated’ among osteoarthritis patients
NATIONAL HARBOR, Md. — A pill developed by AstraZeneca and Pozen that combines a nonsteroidal anti-inflammatory drug with a proton-pump inhibitor was well-tolerated in patients with osteoarthritis, according to a new study.
AstraZeneca announced results of PN400-304, a 12-month study of Vimovo (naproxen and esomeprazole magnesium) delayed-release tablets in patients with osteoarthritis who need daily treatment with NSAIDs but are at risk of NSAID-related gastric ulcers. Vimovo is designed to reduce pain while reducing gastric ulcer risk.
“Many of the 27 million patients in the United States diagnosed with osteoarthritis routinely take NSAIDs to help treat their pain and inflammation,” AstraZeneca executive director for clinical research Mark Sostek said. “The findings from PN400-304 add to the body of data demonstrating that Vimovo is an effective and generally well-tolerated treatment option for osteoarthritis patients at risk of developing NSAID-associated gastric ulcers. In a single tablet, Vimovo delivers both the proven pain relief of naproxen with the gastric ulcer risk reduction of esomeprazole in every dose of the medication.”
Results of the study were presented at the American Academy of Pain Medicine’s annual meeting in National Harbor, Md., and published in the journal Current Medical Research and Opinion.
The Big 3
There are three issues involving over-the-counter medicines today that have put the industry on the defensive, and all involve the question of appropriate access. Drug Store News examined each.
1. FLEXIBLE SPENDING ACCOUNTS
The issue: The Patient Protection and Affordable Care Act required that FSA participants obtain a prescription for those OTCs incorporated into their health savings agenda.
CHPA’s solution: Reverse the rule — it’s likely to cost much more than it will save (see above).
The issue: The maligned decongestant is a key ingredient in the illicit manufacture of methamphetamine. Several states are considering making PSE available by prescription only to help in their war on drugs.
CHPA’s solution: The National Precursor Log Exchange, a multistate tool, wholly funded by the industry, that helps identify methamphetamine-producing criminals while maintaining access for consumers.
According to state government review in Kentucky, at least 97.8% of all PSE sales in the state are made for legitimate use. Rx-only PSE only drives the illegal meth business further underground, where it can’t be tracked as readily by law enforcement.
The issue: Consuming obscene amounts of DXM has become infamous as a cheap and easy “high,” and is highly popular among teenagers predisposed to abusing drugs.
CHPA’s solution: Education and sales restrictions. The CHPA has coordinated with the Partnership for a Drug-Free America (StopMedicineAbuse.org) on a comprehensive awareness initiative to educate parents, teachers and law enforcement on how to recognize and prevent potential teen abuse of cough medicines. The site is promoted on most cold medicine packages. The CHPA also advocates for legislation that would ban DXM sales to minors, as well as legislation to restrict access to unfinished, bulk dextromethorphan.
Statistically, 1.8% of teens between the ages of 12 years and 17 years abuse DXM. And while that number may be too high, teens who report “learning a lot” at home about drugs are 50% less likely to abuse drugs.